Korea Investment Partners

Portfolio Companies 2026 for Korea Investment Partners: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Korea Investment Partners accounts for 25 tracked companies with verified cap-table data, 25 of which disclose round sizes totalling $2.8B. The median disclosed raise is $67M, and the largest is Quantinuum at $925M, ahead of Virogin Biotech ($281M) and Vedanta Biosciences ($169M).

The names that recur most often on these portfolio cap tables are Korea Investment Partners (25 companies), KB Investment (3 companies), Mirae Asset Capital (2 companies), KTB Network (2 companies), Smilegate Investment (2 companies), Boehringer Ingelheim Venture Fund (2 companies). By latest disclosed round, the market skews Series B (6), Series D (5), Series A (5), Series C (3).

Best funded Korea Investment Partners companies

  1. Quantinuum — $925M (latest: Growth)
  2. Virogin Biotech — $281M (latest: Series D)
  3. Vedanta Biosciences — $169M (latest: Series D)
  4. Barogo — $160M (latest: Series C)
  5. Promethera Biosciences — $132M (latest: Series D)
  6. Orum Therapeutics — $120M (latest: Growth)
  7. Pavilion Data Systems, Inc. — $107M (latest: Series D)
  8. OncXerna Therapeutics — $97M (latest: Series B)
  9. Rgenta Therapeutics — $90M (latest: Series A)
  10. Oasis Market — $76M (latest: Late VC)
  11. OncoMyx Therapeutics — $75M (latest: Series B)
  12. PDC*line Pharma — $68M (latest: Series B)
  13. Levit — $67M (latest: Series B)
  14. Fast Five — $56M (latest: Series B)
  15. RideFlux — $52M

Korea Investment Partners — related firms and companies (56)

Korea Investment Partners alternatives · All research reports